John C.M. Farquhar, Director, Chief Executive Officer, on August 21, 2026, sold 27,230 shares in Heartflow (HTFL) for $1,361,500. Following the Form 4 filing with the SEC, Farquhar has control over a total of 360,814 common shares of the company, with 360,814 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1464521/000146452126000139/xslF345X05/form4.xml
Benjamin G Wolff, Director, on August 21, 2026, sold 19,998 shares in Globalstar (GSAT) for $1,644,102. Following the Form 4 filing with the SEC, Wolff has control over a total of 4,116 voting common shares of the company, with 4,116 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1366868/000136861826000011/xslF345X05/wk-form4_1787606843.xml
Jeffrey C Kunins, Chief Product Officer & CTO, on August 21, 2026, sold 9,605 shares in Axon Enterprise (AXON) for $6,019,433. Following the Form 4 filing with the SEC, Kunins has control over a total of 184,029 common shares of the company, with 97,761 shares held directly and 86,268 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1069183/000162828026058683/xslF345X05/wk-form4_1787606325.xml
David Krempa, Chief Business Officer, on August 24, 2026, sold 25,000 shares in Eton Pharmaceuticals (ETON) for $1,626,750. Following the Form 4 filing with the SEC, Krempa has control over a total of 37,025 common shares of the company, with 37,025 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1710340/000143774926028846/xslF345X05/rdgdoc.xml